Overview
Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate and titration-dependent. Serious adverse events were uncommon but more frequent than with placebo in STEP-1.
PubMed citations
Related clinical pages
- STEP trial results
- SELECT trial results
- FLOW trial results
- Mechanism of action
- Dosing & pharmacology
- Contraindications
- Side effects
Key facts, checked November 20, 2026
The Wegovy label lists a boxed warning about thyroid C-cell tumors in rodents and warnings for pancreatitis, gallbladder disease, low blood sugar, kidney injury, allergic reactions, diabetic eye complications, faster heart rate and suicidal thoughts. The Wegovy label lists nausea, diarrhea, vomiting, constipation and abdominal pain among its most common adverse reactions (5% or more of patients); the label raises the dose in steps every four weeks. FDA’s November 9, 2026 safety communication adds a possible increased risk of NAION, a sudden, painless loss of vision in one eye, to every approved GLP-1 label. Report severe stomach pain, signs of gallbladder trouble or any sudden vision change to a clinician promptly.